
Avantor Inc. (AVTR) Stock Forecast & Price Target
Avantor Inc. (AVTR) Analyst Ratings
Bulls say
Avantor Inc. has demonstrated improved financial performance, with both its Life Sciences and Bioprocessing segments achieving expanded adjusted operating margins due to fixed cost leverage, volume growth, and successful cost transformation initiatives. The fourth quarter saw organic revenues increase by 1.0% to $1.69 billion, supported by strong growth in bioprocessing and resilience in the Life Sciences segment, driven by new contracts and enhanced customer relationships. Management's optimistic outlook for FY25 projects continued organic revenue growth of 1.0% to 3.0%, bolstered by an improved end-market mix and anticipated margin expansions stemming from pricing strategies and operational efficiencies.
Bears say
Avantor Inc. faces a negative outlook primarily due to a slowdown in purchasing from small biotech companies, which may lead to revenue declines in that segment. Key financial metrics indicate organic declines in the education & government and advanced technology & applied materials sectors, alongside weaker performance in third-party materials. Additionally, prolonged inventory destocking at customer levels raises concerns regarding future revenue guidance and estimates, further compounding the company's challenges.
This aggregate rating is based on analysts' research of Avantor Inc. and is not a guaranteed prediction by Public.com or investment advice.
Avantor Inc. (AVTR) Analyst Forecast & Price Prediction
Start investing in Avantor Inc. (AVTR)
Order type
Buy in
Order amount
Est. shares
0 shares